About SurgeCare

Surge employs mass cytometry and machine learning algorithms to analyze individual immune responses from a single blood sample, enabling accurate predictions of surgical complications. This technology addresses the 30% risk of postoperative complications by personalizing pre-operative care and optimizing surgical decision-making.

```xml <problem> Surgical complications represent a significant risk, affecting a substantial percentage of patients and leading to increased healthcare costs and prolonged recovery times. Current methods for predicting these complications often lack the precision needed to personalize pre-operative care effectively. This can result in suboptimal surgical decision-making and a higher incidence of adverse outcomes. </problem> <solution> Surge offers PreCyte, a technology that analyzes a patient's immune system from a single blood sample to predict the risk of post-operative complications. PreCyte utilizes mass cytometry to deeply profile the immune system and machine learning algorithms to identify predictive biomarkers. This allows for a more accurate assessment of individual patient risk, enabling clinicians to personalize pre-operative care pathways and optimize surgical strategies. By providing actionable insights derived from complex biological data, PreCyte aims to reduce the incidence of surgical complications and improve patient outcomes. </solution> <features> - Mass cytometry analysis of immune cells from a single blood sample - Proprietary Stabl algorithm for biomarker discovery and identification - Machine learning models for predicting post-operative complication risk - PreCyte SSI product line translating predictive biomarkers into clinical tools - Actionable insights for personalized pre-operative care </features> <target_audience> The primary target audience includes surgeons, hospitals, and healthcare providers seeking to reduce post-operative complications and improve patient outcomes through personalized surgical planning. </target_audience> ```

What does SurgeCare do?

Where is SurgeCare located?

SurgeCare is based in Paris, France.

When was SurgeCare founded?

SurgeCare was founded in 2021.

How much funding has SurgeCare raised?

SurgeCare has raised 10760000.

Location

Paris, France

Founded

2021

Funding

10760000

Employees

19 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

SurgeCare

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

surge.care 1K+

Founded 2021 – Paris, France

Funding

Estimated Funding

$10M+

Team (15+)

No team information available.

Company Description

Problem

Surgical complications represent a significant risk, affecting a substantial percentage of patients and leading to increased healthcare costs and prolonged recovery times. Current methods for predicting these complications often lack the precision needed to personalize pre-operative care effectively. This can result in suboptimal surgical decision-making and a higher incidence of adverse outcomes.

Solution

Surge offers PreCyte, a technology that analyzes a patient's immune system from a single blood sample to predict the risk of post-operative complications. PreCyte utilizes mass cytometry to deeply profile the immune system and machine learning algorithms to identify predictive biomarkers. This allows for a more accurate assessment of individual patient risk, enabling clinicians to personalize pre-operative care pathways and optimize surgical strategies. By providing actionable insights derived from complex biological data, PreCyte aims to reduce the incidence of surgical complications and improve patient outcomes.

Features

Mass cytometry analysis of immune cells from a single blood sample

Proprietary Stabl algorithm for biomarker discovery and identification

Machine learning models for predicting post-operative complication risk

PreCyte SSI product line translating predictive biomarkers into clinical tools

Actionable insights for personalized pre-operative care

Target Audience

The primary target audience includes surgeons, hospitals, and healthcare providers seeking to reduce post-operative complications and improve patient outcomes through personalized surgical planning.